We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merus' Antibody Candidate in Phase II Breast Cancer Study
Read MoreHide Full Article
Merus N.V. (MRUS - Free Report) announced that it has initiated a phase II study to evaluate its most advanced bispecific antibody candidate, MCLA-128, in patients with metastatic breast cancer (“MBC”).
The study comprises two cohorts. The first cohort will evaluate a combination of MCLA-128, Roche’s (RHHBY - Free Report) Herceptin and chemotherapy in MBC patients who are HER2-positive and their disease have progressed after treating with anti-HER2 therapies. The second cohort will evaluate MCLA-128 in combination with endocrine therapy in patients with HR+/HER2-low MBC and whose disease has progressed after treatment with hormone therapies and CDK4/6 inhibitors.
Merus’ shares have increased 15% in the past six months, comparing favorably with the industry’s gain of 2.5% in that period.
Data from pre-clinical study demonstrated that the candidate has shown synergy with Herceptin in blocking heregulin-driven tumor cell growth and blocking of signaling through the HER3 pathway with endocrine therapy as well.
The primary endpoint of the study is to achieve clinical benefit (Complete Response, Partial Response or Stable Disease) at 24-weeks in both the arms. The study will also evaluate progression free survival, overall survival, duration of response and overall response rate among others as its secondary endpoints.
The company is also developing MCLA-128 in early stage studies as a treatment for gastric, ovarian, endometrial and NSCL cancers. Apart from MCLA-128, Merus is also developing another bispecific antibody candidate, MCLA-117, in acute myeloid leukemia.
However, the breast cancer segment is getting lot interest from other large as well as small cap pharma companies. We note that earlier this month, the FDA approved line extension of AstraZeneca’s (AZN - Free Report) PARP inhibitor, Lynparza, to include MBC.
Merus has no approved product in its portfolio. However, it earns revenues as part of its research agreement with Japan-based ONO Pharmaceuticals and collaboration and license agreement with Incyte Corporation (INCY - Free Report) .
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Merus' Antibody Candidate in Phase II Breast Cancer Study
Merus N.V. (MRUS - Free Report) announced that it has initiated a phase II study to evaluate its most advanced bispecific antibody candidate, MCLA-128, in patients with metastatic breast cancer (“MBC”).
The study comprises two cohorts. The first cohort will evaluate a combination of MCLA-128, Roche’s (RHHBY - Free Report) Herceptin and chemotherapy in MBC patients who are HER2-positive and their disease have progressed after treating with anti-HER2 therapies. The second cohort will evaluate MCLA-128 in combination with endocrine therapy in patients with HR+/HER2-low MBC and whose disease has progressed after treatment with hormone therapies and CDK4/6 inhibitors.
Merus’ shares have increased 15% in the past six months, comparing favorably with the industry’s gain of 2.5% in that period.
Data from pre-clinical study demonstrated that the candidate has shown synergy with Herceptin in blocking heregulin-driven tumor cell growth and blocking of signaling through the HER3 pathway with endocrine therapy as well.
The primary endpoint of the study is to achieve clinical benefit (Complete Response, Partial Response or Stable Disease) at 24-weeks in both the arms. The study will also evaluate progression free survival, overall survival, duration of response and overall response rate among others as its secondary endpoints.
The company is also developing MCLA-128 in early stage studies as a treatment for gastric, ovarian, endometrial and NSCL cancers. Apart from MCLA-128, Merus is also developing another bispecific antibody candidate, MCLA-117, in acute myeloid leukemia.
However, the breast cancer segment is getting lot interest from other large as well as small cap pharma companies. We note that earlier this month, the FDA approved line extension of AstraZeneca’s (AZN - Free Report) PARP inhibitor, Lynparza, to include MBC.
Merus has no approved product in its portfolio. However, it earns revenues as part of its research agreement with Japan-based ONO Pharmaceuticals and collaboration and license agreement with Incyte Corporation (INCY - Free Report) .
Merus N.V. Price
Merus N.V. Price | Merus N.V. Quote
Merus carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Top 10 Stocks for 2018
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2018?
Last year's 2017 Zacks Top 10 Stocks portfolio produced double-digit winners, including FMC Corp. and VMware which racked up stellar gains of +67.9% and +61%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2018 today >>